Fig. 4

E2F1 or E2F3 are associated with MYCN amplification or age of diagnosis in neuroblastoma. a Box plots showed the relative E2F1 expression levels in pediatric neuroblastoma patients with age of diagnosis ≥ 18 month or < 18 months in TARGET, GSE16476, GSE85047 and E-MTAB-1781 datasets. b The relative E2F3 expression levels in pediatric neuroblastoma patients with or without MYCN amplification. c The relative E2F3 expression levels in pediatric neuroblastoma patients with age of diagnosis ≥ 18 month or < 18 months. d Forest plots showed the associations of E2F1 expression, E2F3 expression, MYCN amplification and age of diagnosis with the clinical overall survival of pediatric neuroblastoma patients in TARGET, GSE16476, GSE85047 and E-MTAB-1781 datasets. Hazard ratio (HR) and P values were determined using multivariable cox regression assay